Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.270
-0.110 (-7.97%)
At close: Aug 29, 2025, 4:00 PM
1.350
+0.080 (6.32%)
After-hours: Aug 29, 2025, 7:59 PM EDT

Company Description

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases.

The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

It also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease.

In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma.

Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer.

Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals logo
CountryIsrael
Founded2000
IPO DateMar 13, 2014
IndustryBiotechnology
SectorHealthcare
Employees6
CEOAllen Baharaff

Contact Details

Address:
16 Abba Hillel Road
Ramat Gan, 5250608
Israel
Phone972 3 693 8448
Websitegalmedpharma.com

Stock Details

Ticker SymbolGLMD
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001595353
CUSIP NumberM47238106
ISIN NumberIL0011313900
Employer ID98-1147233
SIC Code2834

Key Executives

NamePosition
Allen BaharaffCo-Founder, President, Chief Executive Officer and Chairman
Doron CohenChief Financial Officer
Guy NehemyaChief Operating Officer and Data Protection Officer
Yohai Stenzler CPAChief Accounting Officer
Dr. Liat Hayardeny MBA, Ph.D.Chief Scientific Officer
Dr. Tali GorfineMedical Consultant

Latest SEC Filings

DateTypeTitle
Aug 28, 2025POS AMPost-Effective amendments for registration statement
Aug 28, 2025POS AMPost-Effective amendments for registration statement
Aug 28, 20256-KReport of foreign issuer
Aug 25, 20256-KReport of foreign issuer
Aug 21, 2025EFFECTNotice of Effectiveness
Aug 21, 2025424B3Prospectus
Aug 18, 2025F-1Registration statement for certain foreign private issuers
Aug 15, 20256-KReport of foreign issuer
Aug 14, 20256-KReport of foreign issuer
Aug 14, 2025SCHEDULE 13G/AFiling